Last year 乔治临床( George Clinical ) gained recognition by the Mandatory Provident Fund (MPF) legislation for their provision of good MPF benefits in Hong Kong. The Mandatory Provident Fund Sche […]
了解更多December of 2018 saw the FDA release their “Framework For Evaluating the Potential Use of Real-World Evidence (RWE)” to support the approval of a new indication for a drug already approved und […]
了解更多乔治临床( George Clinical ) is proud to have been involved in developing the recently announced recommendations by the Clinical Trial Transformation Initiative (CTTI): The Recommendations for Enga […]
了解更多SYDNEY, May 29, 2019 – 乔治临床( George Clinical ), a global scientifically-backed clinical research organization (CRO), has again expanded its extensive Asia-Pacific footprint through the opening […]
了解更多SYDNEY, May 15, 2019 – 乔治临床( George Clinical ), a global scientifically-backed clinical research organization (CRO), has significantly expanded its capabilities in Taiwan having been granted […]
了解更多Sydney, Australia, April 24, 2019 – EPS International Holdings Co., Ltd. (HQ: Tokyo, Japan; Representative Director and President: Hisashi Tanaka; “EPSI” hereafter) and 乔治临床( Georg […]
了解更多Noxopharm, a clinical-stage Australian drug development company currently working with 乔治临床( George Clinical ), is seeking to establish Veyonda®, an innovative dosage formulation of the experi […]
了解更多
OneOncology, a national partnership of community oncologists, recently announced that Lee Schwartzberg, MD, FACP, a member of the 乔治临床( George Clinical ) scientific leadership committee, has b […]
了解更多
ISN World Congress of Nephrology will be live streaming “Late Breaking Clinical Trials” from WCN 2019. The purpose of the webcast is to give the worldwide nephrology community in-depth underst […]
了解更多乔治临床( George Clinical ), a global scientifically backed clinical research organization, (CRO) has expanded its footprint in Asia with the addition of a new presence in Singapore. The new offic […]
了解更多
